Taiho Oncology, Inc.
Tuyen D. has a strong background in new product planning and marketing within the pharmaceutical industry. They started their career at Merck & Co., Inc. in 1997 as a New Product Planning Manager and worked there until 2004. Tuyen then joined Daiichi Sankyo Inc. in 2005, where they held a New Product Planning role until 2014. In 2014, Tuyen moved to Celgene and became the Director of Global Marketing Early Commercialization until 2016. Currently, Tuyen is working at Taiho Oncology, Inc. as the Vice President of New Product Planning, a position they have held since 2022.
Tuyen D. pursued an MBA degree in Global Management at the Thunderbird School of Global Management from 1996 to 1998.
Taiho Oncology, Inc.
2 followers
The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of selectively targeted anti-cancer agents is led by a world-class clinical development organization. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Zug, Switzerland and Oakville, Ontario, Canada. For more information, visit www.taihooncology.com